PAREXEL’S Head of Biopharm Unit Named to the 2016 PharmaVOICE 100
BOSTON, August 15, 2016— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that PharmaVOICE magazine selected Ubavka DeNoble, MD, Corporate Vice President, as one of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2016 issue of PharmaVOICE, recognizes Dr. DeNoble for her innovative thinking, passion and fervor for the industry, and dedication to mentoring the next generation of leaders.
At PAREXEL, Dr. DeNoble leads the Company’s BioPharm unit, a dedicated team focused on the unique needs of small and mid-sized biopharmaceutical companies. The BioPharm team collaborates with clients to optimize processes associated with clinical trial implementation, such as study start-up and patient recruitment, to accelerate drug development for these companies.
“We are proud that Ubavka DeNoble is one of this year’s PharmaVOICE 100,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “Ubavka demonstrates her leadership, vision, and dedication through her steadfast commitment to our employees and our clients. Every day, she inspires those around her by exemplifying PAREXEL’s High Performance Culture values, including open communication, teamwork, innovation, and client service and quality.”
The annual PharmaVOICE 100 list honors a select group of leaders in the life sciences who positively impact their colleagues, peers, organizations, and the industry at large. These individuals are passionate, forward-thinkers who actively confront industry challenges and trends. To read the 2016 PharmaVOICE profiles, visit www.pharmavoice.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement.
PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and had approximately 18,600 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #